Agenus Inc is a biotechnology company focused on discovering and developing immuno-oncology therapies that harness the body’s immune system to fight cancer
The company is engaged in research and innovative solutions for a range of cancer treatments, including checkpoint inhibitors and other immunotherapeutics. With an emphasis on enhancing patient outcomes, Agenus collaborates with various partners to advance its pipeline of therapeutic candidates and facilitate the development of novel approaches to cancer treatment. The company's commitment to expanding immuno-oncology options aims to improve the overall effectiveness of cancer therapies and patient quality of life.
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The results will support regulatory submissions to the FDA and EMA.
Agenus reports that Bristol Myers Squibb (NYSEBMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy adjustments.
Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and balstilimab, for relapsed/refractory microsatellite-stable colorectal cancer. William Blair downgrades due to financial challenges and uncertain regulatory pathway.
Agenus shares drop amid FDA's feedback on its immunotherapy combo botensilimab and balstilimab for colorectal cancer. The FDA advised against accelerated approval, citing concerns about survival benefits. Agenus is progressing with European regulatory discussions.
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
